Sign in

Private company

Vitro Biopharma, Inc.

Vitro Biopharma, Inc. is an American biological products company based in Golden, incorporated in Nevada.1

Last updated Oct 21, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersDenver, Colorado1
  • Incorporated inNV2
  • Business address3200 Cherry Creek Drive South, Suite 410, Denver, Co 802092
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Cells and generates increased ATP expression (an energy molecule), viability, immunosuppression measurement and yield.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

76.5%Gross margin5
-244.2%Operating margin5
-527.6%Net margin5
10.8%Revenue growth, 20255
-$2.5MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue7¢$483.3K
  • Research and development8¢$533.0K
  • Selling, general and admin86¢$6.1M

Out of $2.1M in revenue.5 The company lost money this year.

Financial statements

Revenue6785$2.1M in 2025+2544% since 2015
0$1.0M$2.0M$3.0M$4.0M2015: $77.8K$77.8K20152022: $3.3M$3.3M2022+4133%2023: $1.8M$1.8M2023−46%2024: $1.9M$1.9M2024+5%2025: $2.1M$2.1M2025+11%
Gross profit6785$1.6M in 2025+2395% since 2015
0$1.0M$2.0M$3.0M2015: $63.1K$63.1K20152022: $2.7M$2.7M2022+4192%2023: $1.5M$1.5M2023−46%2024: $1.4M$1.4M2024−2%2025: $1.6M$1.6M2025+10%
Operating income6785-$5.0M in 2025+3076% since 2015
-$10.0M-$7.5M-$5.0M-$2.5M02015: -$158.1K-$158.1K20152022: -$6.0M-$6.0M2022+3673%2023: -$5.4M-$5.4M2023−10%2024: -$9.2M-$9.2M2024+70%2025: -$5.0M-$5.0M2025−45%
Net income6785-$10.9M in 2025+4314% since 2015
-$15.0M-$10.0M-$5.0M02015: -$245.9K-$245.9K20152022: -$6.9M-$6.9M2022+2690%2023: -$5.4M-$5.4M2023−22%2024: -$9.9M-$9.9M2024+84%2025: -$10.9M-$10.9M2025+10%
Fiscal year2015201620212022202320242025
Revenue$77.8K6$3.3M7$1.8M8$1.9M5$2.1M5
Cost of revenue$21.7K6$586.9K7$298.1K8$426.2K5$483.3K5
Gross profit$63.1K6$2.7M7$1.5M8$1.4M5$1.6M5
Research and development$152.0K6$155.6K7$206.4K8$618.3K5$533.0K5
Selling, general and admin$83.9K6$7.6M7$6.1M8$6.6M5$6.1M5
Operating expenses-$3.0M5-$2.7M5
Operating income-$158.1K6-$6.0M7-$5.4M8-$9.2M5-$5.0M5
Interest$87.7K6$198.4K7$270.2K7
Income tax
Net income-$245.9K6-$6.9M7-$5.4M8-$9.9M5-$10.9M5
Earnings per share-$1.877-$1.218-$2.215-$2.445
Earnings per share (diluted)-$1.877-$1.218-$2.215-$2.445
Shares (weighted, basic)4.1M shares74.4M shares84.5M shares54.5M shares5
Shares (weighted, diluted)4.1M shares74.4M shares84.5M shares54.5M shares5

Compare Vitro Biopharma, Inc. with another company

Corporate structure

Vitro Biopharma, Inc. sits at the top of its group. 3 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Vitro Biopharma, Inc.

  • Jack Zamora Filed SC 13G on Vitro Biopharma, Inc., latest Feb 15, 2023
  • James R. Musick Filed SC 13G on Vitro Biopharma, Inc., latest Feb 14, 2023
  • Christopher Furman Filed SC 13D on Vitro Biopharma, Inc., latest Dec 2, 2022
  • Vitro Biopharma, Inc. Denver, Colorado
    • Fitore Inc. Subsidiary · Florida, United States
    • InfiniVive MD, LLC Subsidiary · Colorado, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Vitro Biopharma, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Leasehold improvements$12.8K5 Oct 31, 2025$12.8K5 Oct 31, 20240%
Property and equipment, before depreciation$1.1M5 Oct 31, 2025$1.1M5 Oct 31, 2024+0.5%
Accumulated depreciation$1.0M5 Oct 31, 2025$920.2K5 Oct 31, 2024+11.1%
Property and equipment, net$42.2K5 Oct 31, 2025$139.6K5 Oct 31, 2024−69.8%
Finance-lease assets$3.4K5 Oct 31, 2024$33.3K8 Oct 31, 2023−89.9%
Operating-lease assets (leased space)$360.7K5 Oct 31, 2025$481.8K5 Oct 31, 2024−25.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$3.2M5 Oct 31, 2025$3.2M5 Oct 31, 20240%
Intangible assets, net (excluding goodwill)$327.6K5 Oct 31, 2025$358.1K5 Oct 31, 2024−8.5%
Finite-lived intangibles, gross$1.5M5 Oct 31, 2025$1.5M8 Oct 31, 20240%
Accumulated amortization-$366.4K5 Oct 31, 2025-$336.0K5 Oct 31, 2024−9.1%
Finite-lived intangibles, net$327.6K5 Oct 31, 2025$152.4K8 Oct 31, 2024+115.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$134.8K5 Oct 31, 2025$115.4K5 Oct 31, 2024+16.9%
Finished goods$134.8K5 Oct 31, 2025$115.4K5 Oct 31, 2024+16.9%

Properties, in its own words

We lease two separate office or laboratory facilities for our business and operations. Our executive offices are located in Denver, Colorado where we occupy approximately 2,978 square feet of office space under a lease until December 31, 2026 at a rate of $7,693 per month, plus operating expenses with certain escalations through December 31, 2026. Our manufacturing and administrative offices and facilities are currently located at 4621 Technology Drive, Golden Colorado, where we lease approximately 3,100 square feet under a 10-year lease commencing July 1, 2020 and which provides us with several options to renew upon expiration for additional 5-year terms. The lease is with an affiliate of our Chief Science Officer. The rent is $5,645 per month plus taxes, insurance and utilities.

Item 2 of the 10-K filed Feb 13, 2026.4

Leadership

Who has led Vitro Biopharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. James R. Musick2006–2014
  2. Christopher Furman2022–2023

Chair

  1. Caroline Mosessian2022

President

  1. James R. Musick2006–2014

Chief financial officer

  1. Nathan Haas2022
2010201520202025
Board members and other officers (8)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerThomas Ohrt named Jun 11, 202521
  • Chief Manufacturing OfficerTiana R States named Apr 5, 2023 to Dec 1, 202322
  • DirectorJohn Evans named Oct 20, 202123

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Fitore Inc. Florida3
  • InfiniVive MD, LLC Colorado3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • VITRO DIAGNOSTICS INCDec 13, 1996 to Oct 20, 20212

Timeline

  1. Jul 22, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares24
  2. Jun 27, 20248-K Entered a material agreement; Unregistered sale of shares25
  3. May 17, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares26
  4. Apr 17, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares27
  5. Jan 23, 20248-K Executive or director change; Other events28
  6. Jan 16, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares29
  7. Nov 22, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares30
  8. Jul 19, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares31
  9. Jul 7, 20238-K Change to shareholders' rights; Bylaws or fiscal year changed32
  10. Jun 16, 20238-K Entered a material agreement; Unregistered sale of shares33
  11. Jun 8, 20238-K Entered a material agreement; Unregistered sale of shares34
  12. May 12, 20238-K Entered a material agreement; Unregistered sale of shares35
  13. Nov 14, 2022New chief executive Christopher Furman becomes CEO11
  14. Dec 15, 2006New chief executive James R. Musick becomes CEO12

Filings

117 filings to the SEC since October 2021: 4 annual reports, 12 quarterly reports, 19 major events, 7 insider forms, 3 large holders, 5 private raises, 67 other. The latest 20:

  1. Sep 18, 202610-Q EDGAR
  2. Sep 14, 2026NT 10-Q EDGAR
  3. Jun 15, 202610-Q EDGAR
  4. Mar 16, 202610-Q EDGAR
  5. Feb 13, 202610-K EDGAR
  6. Jan 29, 2026NT 10-K EDGAR
  7. Sep 12, 202510-Q EDGAR
  8. Jun 20, 202510-Q EDGAR
  9. Jun 16, 2025NT 10-Q EDGAR
  10. Jun 11, 2025D EDGAR
  11. Mar 20, 202510-Q EDGAR
  12. Mar 17, 2025NT 10-Q EDGAR
  13. Jan 28, 202510-K EDGAR
  14. Sep 16, 202410-Q EDGAR
  15. Sep 11, 2024EFFECT EDGAR
  16. Sep 10, 2024CORRESP EDGAR
  17. Sep 10, 2024CORRESP EDGAR
  18. Sep 5, 2024S-1/A EDGAR
  19. Aug 29, 2024CORRESP EDGAR
  20. Aug 29, 2024UPLOAD EDGAR

The 117 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. May 27, 2025Raised $100,000 in a private offering of equity Form D: $15 million offered in all Form D
  2. Nov 16, 2023Raised $2 million in a private offering of debt Form D: $3 million offered in all Form D
  3. Jan 6, 2023Raised $992,600 in a private offering of debt Form D: $2.5 million offered in all Form D
  4. Oct 15, 2021Raised $3 million in a private offering of debt Form D: $10 million offered in all Form D

SEC filer profile

How Vitro Biopharma, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARVitro Biopharma, Inc.1
  • CIK0000793171
  • Employer ID (EIN)84-10120424
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inNevada4
  • Fiscal year endsOctober 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address3200 Cherry Creek Drive South, Suite 410, Denver, CO 802091
  • Phone85584876271
  • Shares outstanding4,517,651 as of Sep 18, 202610
  • Public float$0 as of Apr 30, 20255
  • AuditorMaloneBailey, LLP, Houston, Texas PCAOB ID 206; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceOct 23, 19961
  • Filings369 in all: 8-K (66), 10QSB (38), 10-Q (34), CORRESP (30), NT 10-Q (22), UPLOAD (17), NT 10-K (16), SC 13D/A (14)1
    All 38 form types

    10KSB (13), 4 (13), 10-K (12), 3 (12), S-1/A (12), 8-K/A (8), 5 (7), D (7), 4/A (6), SC 13D (6), 10-Q/A (4), 10QSB/A (4), 10-12G/A (3), PRE 14A (3), SC 13G (3), 10KSB/A (2), 144 (2), D/A (2), DEF 14A (2), 10-12G (1), 10-K/A (1), 3/A (1), 8-A12B (1), CERT (1), EFFECT (1), NTN 10Q (1), REGDEX (1), REVOKED (1), S-1 (1), SC 13G/A (1)

  • Latest filingsAnnual report (10-K) Feb 13, 2026
    Quarterly report (10-Q) Sep 18, 2026
    Proxy statement (DEF 14A) Feb 28, 2001
    Latest 8-K (8-K) Jul 22, 2024

Risk factors and legal proceedings

The risks Vitro Biopharma, Inc. names in Item 1A of its 10-K filed Feb 13, 2026: 72 risks under these headings, as written.4

  • Risks Related To Our Financial Condition
  • Risks Related To Our Business
  • Risks Related To Intellectual Property
  • Risks Related To Regulatory Approval And Other Government Regulations
  • Additional Risks Related To Our Supply Arrangements With Third-Party Foreign Medical Centers
  • Risks Related To Ownership Of Our Common Stock
  • Implications of Being a Smaller Reporting Company
  • As described in the report of our auditors for the years ended October 31, 2025 and 2024 and the notes to our consolidated financial statements, there is substantial doubt about our ability to continue as a going concern, and if we are unable to continue, you may lose your entire investment.
  • We have limited revenue and cash flow and are dependent on improving operations, along with receipt of additional working capital, to fund continued development and implementation of our business plan, and our failure to obtain this capital may cause the partial or total loss of your investment.
  • We have incurred substantial losses in recent years and may never be profitable.
  • The acquisitions of our two subsidiaries were completed in 2021 and we may not successfully grow those businesses to be profitable and contribute to our cash flow.
  • A significant portion of our revenue has been concentrated on a few large customers and if we lose customers, our results of operations would be expected to be further adversely impacted.
The other 65 risks
  • Servicing our debt may require a significant amount of cash. We may not have sufficient cash flow from our business to pay our indebtedness.
  • Our ability to recognize the benefits of deferred tax assets is dependent on future cash flows and taxable income.
  • The use of our product candidates and our other products, including AlloRx Stem Cells, InfiniVive MD products, MSC-Gro, CAFs and our other products, or any future products in individuals may expose us to product liability claims, and we may not be able to obtain adequate product liability insurance.
  • In order to successfully implement our plans and strategies, we will need to grow our organization, and we may experience difficulties in managing this growth.
  • Security and privacy breaches, computer viruses, and cyber-attacks could harm our business, financial condition, results of operations, or reputation.
  • We have in the past and may in the future enter into transactions that give rise to conflicts of interest with our affiliates and related parties and such transactions may harm our business and financial condition if they are not structured in our best interest.
  • Risks Related to our Business
  • We are heavily dependent on the successful development and commercialization of AlloRx Stem Cell therapy, and if we encounter delays or difficulties in the development of this product candidate, we may not generate sufficient revenue to continue our business operations and our business could be harmed.
  • If the potential of our product candidates, particularly AlloRx Stem Cell therapy, to treat various diseases and conditions is not realized, the value of our technology and our development programs could be significantly reduced.
  • We have never commercialized a biologic or drug product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products if we attain an EUA or other regulatory approval for commercialization of AlloRx Stem Cell therapy or any other product candidates.
  • We have a limited operating history with our current business model, which may make it difficult for you to evaluate our current business and predict our future success and viability.
  • Our product development programs are based on novel technologies and are inherently risky.
  • There are no FDA-approved allogeneic, cell-based therapies for PTHS, Long COVID, Lupus (SLE), MS, Alzheimer’s disease, or many other indications targeted by AlloRx Stem Cell therapy, our lead investigational product candidate. This could complicate and delay FDA approval of our product candidate for these indications.
  • Our product candidates represent new classes of therapy that the marketplace may not understand or accept.
  • If we are not able to recruit and retain additional qualified management and scientific personnel, we may fail in obtaining financing, pursuing collaborations or developing our technologies and product candidates.
  • We may, in the future, enter into arrangements with third-party collaborators to help us develop our product candidates and commercialize our products, and our ability to commercialize such products may be impaired or delayed if collaborations are unsuccessful.
  • We rely on third-party healthcare professionals to administer AlloRx Stem Cell therapy and AlloRx Stem Cells to patients, and our business could be harmed if these third parties administer these incorrectly or fail to follow our instructions or recommendations.
  • Our business would be adversely affected if our relationships with third-party healthcare professionals on which we rely were disrupted.
  • We may be dependent on third parties for the manufacture or distribution of any product candidates, and any problems experienced by these third parties could result in a delay or interruption in the supply of our product candidate in our clinical trials and any future approved products.
  • We will be reliant on third parties to conduct, manage, and monitor our clinical studies, and if those third parties perform in an unsatisfactory manner, it may harm our business.
  • Favorable results from compassionate use treatment or initial interim results from a clinical trial do not ensure that later clinical trials will be successful and success in early-stage clinical trials does not ensure success in later-stage clinical trials.
  • Interim, “topline” and preliminary data from our clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on other product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • If our competitors develop similar or comparable treatments for the target indications of our product candidates that are approved more quickly, marketed more successfully or are demonstrated to be safer or more effective than our product candidates, or if FDA approves biosimilar competitors to our products post-approval, our commercial opportunity will be reduced or eliminated.
  • MSCs are biological entities obtained from living humans that can pose risks to the recipient. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly. We may incur significant costs to comply with current or future environmental, health and safety laws and regulations.
  • Our product candidates are derived from human UCs and therefore have the potential for disease transmission.
  • Ethical and other concerns surrounding the use of stem cell therapy or human tissue may negatively affect public perception of us or our products or product candidates or may negatively affect regulatory approval of our products or product candidates, thereby reducing demand for our products.
  • The successful commercialization of our current or future product candidates will depend on obtaining reimbursement from government and third-party payors.
  • A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.
  • Biotechnology is a well-capitalized area, and as a result, we may not be able to keep up with other well-capitalized companies in the market.
  • If our intellectual property does not adequately protect our products and uses, others could compete against us more directly, which could harm our business and have a material adverse effect on our business, financial condition, and results of operations.
  • If we fail to obtain assignment of rights of our intellectual property from all inventors or fail to obtain assignment of rights of our intellectual property in a timely fashion, we may not own or exclusively own our intellectual property, and this could adversely affect our ability to protect our product and have a materially effect on our business.
  • If we are unable to protect the confidentiality of our proprietary information, trade secrets, and know-how, our competitive position could be impaired and our business, financial condition, results of operations, and prospects could be adversely affected.
  • Third-party claims of patent infringement may prevent or delay our product development efforts.
  • We may become involved in lawsuits to protect or enforce any patents we might obtain in the future, which could be expensive and time consuming.
  • Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common stock to decline.
  • Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.
  • Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
  • If we do not obtain patent term extension for our product candidates and/or methods of their use, our business may be materially harmed.
  • We may not be able to protect our intellectual property rights throughout the world.
  • If we are not able to conduct our clinical trials properly and on schedule, marketing approval by FDA and other regulatory authorities may be delayed or denied.
  • Producing and marketing an approved drug or other medical product is subject to significant and costly post-approval regulation.
  • If we violate the guidelines pertaining to promotion and advertising of our clinical candidates or approved products, either inadvertently or otherwise, we may be subject to disciplinary action by the FDA’s Office of Prescription Drug Promotion (“OPDP”) or other regulatory bodies.
  • We and any of our future development partners will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.
  • Our business could target benefits from various regulatory incentives, such as orphan drug exclusivity, breakthrough therapy designation, fast track designation, and priority review, but we may not ultimately qualify for or benefit from these incentives.
  • Obtaining and maintaining regulatory approval of a product in one jurisdiction does not mean that we will be successful in obtaining or maintaining regulatory approval in other jurisdictions.
  • The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
  • The FDA and other comparable foreign regulatory authorities may not accept data from trials or studies conducted in locations outside of their jurisdiction.
  • We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through an expedited review program, and if we are unable to do so, then we could face increased expense to obtain, and delays in the receipt of, necessary marketing approvals.
  • Our research and development activities could be affected or delayed due to possible restrictions on animal testing.
  • We may face difficulties from changes to current statutes or regulations and future legislation or regulations, both in the U.S. as well as in other foreign jurisdictions where we may be operating.
  • Our relationships with healthcare providers, clinical investigators, CROs and third-party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings.
  • Risks Related To The Cosmetic Product Industry And InfiniVive MD Products
  • A recall or suspension of sale of our InfiniVive MD products, or the discovery of serious safety issues with our products or the incorrect application of such products by medical professionals to which we sell such products, could have a significant negative impact on us.
  • InfiniVive MD products may fail to achieve the broad degree of physician adoption and use or consumer demand necessary for commercial success.
  • FDA and FTC may undertake enforcement action against our cosmetic products if they do not accept our advertising and marketing or if those products are used beyond the intended uses that we authorize.
  • If we fail to develop and maintain our InfiniVive MD brand, our business could suffer.
  • Our InfiniVive MD brand and reputation may be diminished due to real or perceived quality, safety, efficacy or environmental impact issues with its products, which could have an adverse effect on our business, financial condition, results of operations and prospects.
  • The cosmetics industry is highly competitive, and if InfiniVive MD’s products are unable to compete effectively our results will suffer.
  • Risks Related To The Dietary And Nutritional Supplements Industry And Fitore Products REMOVE?
  • Adulterated or misbranded products appearing on the market under the Fitore brand may subject us to costs or liabilities or damage our reputation and brand.
  • We and our suppliers are subject to numerous laws and regulations that apply to the manufacture, sale and marketing of products that promote health and wellness, including cosmetics, dietary supplements, and other personal care products, and compliance with these laws and regulations, as they currently exist or as modified in the future, may increase our costs, limit or eliminate our ability to sell certain products, subject us or our suppliers to the risk of enforcement action, or otherwise adversely affect our business, results of operations and financial condition.
  • If Fitore’s products cause undesirable side effects, our business may suffer.
  • FDA could prohibit us from exporting products for use in compassionate use programs or clinical studies in foreign jurisdictions.
  • FDA, FTC, and other regulatory agencies actively enforce against medical tourism companies and medical providers advertising to patients in the United States if the claims or procedures are not substantiated or in compliance with the local countries’ laws.
  • A substantial portion of our sales of AlloRx Stem Cells for use in foreign clinical studies are completed on a purchase order basis without any written agreements. Such customers may issue fewer or smaller purchase orders than we expect under our current arrangements, which could negatively impact our revenues. In addition, although these purchase orders are generally not cancelable, such customers may decide to delay or cancel orders, which could also negatively impact our revenues.
  • Risks Related to Ownership of our Common Stock
  • Our principal stockholders and management, including our Chief Science Officer and our former Chief Executive Officer in particular, own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

Legal proceedings

From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. No legal proceedings, government actions, administrative actions, investigations, or claims are currently pending against us or our officers and directors in which we are adverse. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38